Shanghai Jiatan Pharmatech Co., Ltd Report issue

Government Phase 2 Phase 3

Organization Overview

First Clinical Trial
2018
NCT03730142
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Shang hai Jiatan Pharma | Shanghai Jiatan Pharmatech Co., Ltd

Active Ingredients

Drugs in Phase 3 Trials (2)

bedaquiline (sirturo) (2 trials)

wx-081 (3 trials)

Drugs in Phase 2 Trials (2)

toripalimab (LOQTORZ) (2 trials)

wxfl10030390 (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 1)

Tuberculosis (Phase 2)

Tuberculosis, Pulmonary (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 4